BR112021026089A2 - Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos - Google Patents
Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmosInfo
- Publication number
- BR112021026089A2 BR112021026089A2 BR112021026089A BR112021026089A BR112021026089A2 BR 112021026089 A2 BR112021026089 A2 BR 112021026089A2 BR 112021026089 A BR112021026089 A BR 112021026089A BR 112021026089 A BR112021026089 A BR 112021026089A BR 112021026089 A2 BR112021026089 A2 BR 112021026089A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- same
- binding fragments
- antigen binding
- antibody
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Abstract
fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos. esta divulgação refere-se a composições com um fragmento de ligação de anticorpo que se liga especificamente a cd3 ou um epítopo do mesmo. algumas modalidades incluem composições e fragmentos de ligação a anticorpos com maior estabilidade. também são divulgadas proteínas de fusão biespecíficas incluindo estes fragmentos de ligação a anticorpos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866746P | 2019-06-26 | 2019-06-26 | |
US202063041059P | 2020-06-18 | 2020-06-18 | |
PCT/US2020/039673 WO2020264200A1 (en) | 2019-06-26 | 2020-06-25 | Cd3 antigen binding fragments and compositions comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026089A2 true BR112021026089A2 (pt) | 2022-03-22 |
Family
ID=74059962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026089A BR112021026089A2 (pt) | 2019-06-26 | 2020-06-25 | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos |
Country Status (16)
Country | Link |
---|---|
US (2) | US20230121775A1 (pt) |
EP (1) | EP3990497A4 (pt) |
JP (1) | JP2022537824A (pt) |
KR (1) | KR20220038068A (pt) |
CN (1) | CN115175933A (pt) |
AU (1) | AU2020308868A1 (pt) |
BR (1) | BR112021026089A2 (pt) |
CA (1) | CA3143519A1 (pt) |
CL (1) | CL2021003448A1 (pt) |
CO (1) | CO2022000406A2 (pt) |
CR (1) | CR20210628A (pt) |
EC (1) | ECSP22005986A (pt) |
IL (1) | IL289102A (pt) |
MX (1) | MX2021015880A (pt) |
PE (1) | PE20220600A1 (pt) |
WO (1) | WO2020264200A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021507706A (ja) * | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
US11512113B2 (en) | 2020-08-11 | 2022-11-29 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
KR20230135575A (ko) | 2020-12-09 | 2023-09-25 | 재눅스 테라퓨틱스 인크. | Psma 및 이펙터 세포 항원을 표적화하는 종양 활성화항체와 관련된 조성물 및 방법 |
WO2023092099A1 (en) * | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2625440C (en) * | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
US8846042B2 (en) * | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
CN106062206A (zh) * | 2014-01-15 | 2016-10-26 | 酵活有限公司 | 双特异性cd3和cd19抗原结合构建体 |
BR112017001579A2 (pt) * | 2014-07-25 | 2017-11-21 | Cytomx Therapeutics Inc | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos |
WO2017040344A2 (en) * | 2015-08-28 | 2017-03-09 | Amunix Operating Inc. | Chimeric polypeptide assembly and methods of making and using the same |
JP2021507706A (ja) * | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
US20230287040A1 (en) * | 2019-11-13 | 2023-09-14 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
-
2020
- 2020-06-25 US US17/621,993 patent/US20230121775A1/en active Pending
- 2020-06-25 BR BR112021026089A patent/BR112021026089A2/pt unknown
- 2020-06-25 CN CN202080061316.5A patent/CN115175933A/zh active Pending
- 2020-06-25 EP EP20833432.6A patent/EP3990497A4/en active Pending
- 2020-06-25 KR KR1020227002573A patent/KR20220038068A/ko unknown
- 2020-06-25 PE PE2021002228A patent/PE20220600A1/es unknown
- 2020-06-25 CR CR20210628A patent/CR20210628A/es unknown
- 2020-06-25 WO PCT/US2020/039673 patent/WO2020264200A1/en unknown
- 2020-06-25 JP JP2021576275A patent/JP2022537824A/ja active Pending
- 2020-06-25 AU AU2020308868A patent/AU2020308868A1/en active Pending
- 2020-06-25 MX MX2021015880A patent/MX2021015880A/es unknown
- 2020-06-25 CA CA3143519A patent/CA3143519A1/en active Pending
- 2020-08-19 US US16/996,899 patent/US20210054077A1/en not_active Abandoned
-
2021
- 2021-12-19 IL IL289102A patent/IL289102A/en unknown
- 2021-12-22 CL CL2021003448A patent/CL2021003448A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000406A patent/CO2022000406A2/es unknown
- 2022-01-25 EC ECSENADI20225986A patent/ECSP22005986A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020308868A1 (en) | 2022-01-20 |
CL2021003448A1 (es) | 2022-09-09 |
KR20220038068A (ko) | 2022-03-25 |
CO2022000406A2 (es) | 2022-05-31 |
CN115175933A (zh) | 2022-10-11 |
EP3990497A1 (en) | 2022-05-04 |
IL289102A (en) | 2022-02-01 |
EP3990497A4 (en) | 2023-07-19 |
PE20220600A1 (es) | 2022-04-25 |
CA3143519A1 (en) | 2020-12-30 |
CR20210628A (es) | 2022-03-22 |
MX2021015880A (es) | 2022-03-22 |
WO2020264200A1 (en) | 2020-12-30 |
JP2022537824A (ja) | 2022-08-30 |
ECSP22005986A (es) | 2022-04-29 |
US20210054077A1 (en) | 2021-02-25 |
US20230121775A1 (en) | 2023-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021026089A2 (pt) | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos | |
CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
BR112013027021A2 (pt) | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
BR112022001368A2 (pt) | Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos | |
BR112021017801A2 (pt) | Anticorpos biespecíficos anti-vbeta17/anti-cd123 | |
BR112022011669A2 (pt) | Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica | |
ECSP22055004A (es) | Anticuerpos anti?mertk y m?todos de uso de los mismos | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
CL2021002792A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
RU2017124512A (ru) | Способ определения антител, вызывающих комплемент-зависимую цитотоксичность | |
CL2020002459A1 (es) | Variantes de anticuerpo c-terminales | |
BR112022004570A2 (pt) | Terapia de combinação com anticorpos entpd2 e cd73 | |
EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
AR119982A1 (es) | Terapias de combinación con anticuerpos entpd2 | |
CO2022000404A2 (es) | Fragmentos de unión a antígeno egfr y composiciones que los comprenden | |
BR112023021256A2 (pt) | Anticorpos humanos para artemina e métodos de uso dos mesmos | |
EA202191187A1 (ru) | Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение |